• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Eli Lilly’s blowout quarter has a $5.5 billion twist

by October 29, 2026
written by October 29, 2026

Eli Lilly LLY reported better-than-expected earnings for its fiscal Q3 on Thursday, offering fresh evidence that helps justify its trillion-dollar market cap.

Sales reached $24.4 billion, while adjusted earnings came in at $7.48. But the bigger development was management’s sharply higher revenue guidance even as acquisition-related charges pushed its profit forecast lower.

At the time of writing, Eli Lilly stock is up more than 50% versus its year-to-date low.

Lower prices are bringing more business to Eli Lilly

Lilly’s results strengthen the argument that expanding access to its medicines can outweigh falling prices.

Sales volumes increased 53%, overcoming a 15% decline in realized prices.

More encouragingly, adjusted gross margin improved year over year, suggesting pricing pressure has yet to overwhelm manufacturing efficiencies and a favorable product mix.

For shareholders, that provides evidence that cheaper access need not derail profitable growth.

The crucial question is whether additional prescriptions continue arriving fast enough to compensate for lower revenue per treatment.

There’s also a concentration risk: Mounjaro and Zepbound made up roughly two-thirds of LLY’s revenue. Their success increasingly determines Lilly’s performance, leaving investors sensitive to competitive threats or reimbursement changes affecting those franchises.

Why LLY’s trimmed profit forecast needs context

Lilly raised its full-year sales outlook by $5.5 billion to $91 billion. Yet, its adjusted earnings outlook dropped to $35.5 per share at the midpoint of the guided range.

Acquisition-related research charges explain the divergence: management said stronger underlying earnings expectations were more than offset by charges associated with its dealmaking.

The investment implication is that the lower profit forecast does not, by itself, indicate weakening demand or deteriorating execution.

Nevertheless, those charges deserve scrutiny.

Buying experimental treatments commits shareholder capital to uncertain future returns.

Investors can recognize the strength of Lilly’s existing business while still asking whether its acquisitions will eventually produce enough commercially successful medicines to justify their cost.

What would determine Lilly’s trajectory moving forward

Eli Lilly’s newer obesity pill, Foundayo, generated $184 million in quarterly sales, falling short of expectations.

That introduces a more cautious element into an otherwise strong report: dominance in injectable treatments does not guarantee an equally commanding position in oral medicines.

For investors, the pill’s progress matters because it could broaden Lilly’s customer base and reduce reliance on its established injection franchises.

Future quarters must demonstrate that it can become a meaningful additional growth engine. The immediate sales beat also needs perspective.

Revenue benefited from approximately $900 million in milestones and favorable rebate and discount adjustments.

Those benefits make the headline growth rate a less reliable guide to repeatable demand.

Sustaining the rally will require continued prescription growth and successful launches beyond this quarter’s favorable adjustments.

Wall Street currently has a Buy rating on Eli Lilly stock.

The post Eli Lilly’s blowout quarter has a $5.5 billion twist appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Bloomberg among firms getting faster access to Trump posts: why is it controversial?
next post
Amazon earnings: can AWS growth satisfy Wall Street as capex rises

related articles

SpaceX stock rises as Citi sees wireless network...

November 18, 2026

Why is Nvidia stock falling over 2% on...

November 18, 2026

Cathie Wood was right on the money about...

November 18, 2026

When could Anthropic stock join the MSCI, Russell,...

November 18, 2026

Nvidia earnings: investors still need answers to two...

November 18, 2026

Strategy stock falls as analyst warns MSTR could...

November 18, 2026

Can Anthropic IPO beat SpaceX to become the...

November 18, 2026

Google stock analysis: may benefit from Anthropic IPO...

November 18, 2026

Nasdaq rises as Nvidia forecast lifts stocks; Anthropic...

November 18, 2026

Why Micron stock is falling despite strong Nvidia...

November 18, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Western Digital stock surges as Morgan Stanley lifts target to $650

    June 15, 2026
  • China stocks hit bear market after 10-week rout: is 20% crash just the start?

    October 22, 2026
  • Apple price hikes unlikely to hurt demand, JPMorgan says as it raises PT

    July 8, 2026
  • European stocks close lower as bond yields and oil offset Anthropic-driven tech rally

    September 29, 2026
  • SanDisk stock keeps plunging, so why are analysts raising price targets?

    July 14, 2026

Popular Posts

  • 1

    Why SpaceX stock is down around 3% on Tuesday

    September 15, 2026
  • 2

    Micron stock falls 4%, why this analyst sees 40% upside for the stock?

    September 28, 2026
  • 3

    Evening digest: US jobs cool, gold falls as Treasury yields rise

    October 2, 2026
  • 4

    Nike stock sinks after earnings as its comeback plan turns into more layoffs

    October 2, 2026
  • 5

    Intel, AMD stocks slide again in aftermath of Broadcom’s weak outlook

    June 5, 2026

Categories

  • Editor's Pick (711)
  • Investing (2,626)
  • Stock (90)

Latest Posts

  • Why is Oracle stock falling nearly 6% on Monday?

    November 2, 2026
  • Dow slips 45 points as tech sell-off deepens on AI and chip stock weakness

    June 23, 2026
  • US yields just hit a 19-year high: these 5 stocks could take the biggest hit

    September 15, 2026

Recent Posts

  • Tesla stock rises 5% on Roadster reveal, but analysts question financial impact

    October 16, 2026
  • US CPI today: 5 stocks that could explode if inflation delivers a surprise

    September 11, 2026
  • CEO under fire for mass layoffs amid foreign worker hiring spree now appointed to Fed’s task force on jobs

    July 10, 2026

Editor’s Pick

  • Why Apple sued OpenAI: everything to know about the AI trade secrets lawsuit

    July 13, 2026
  • Unearthed: El-Sayed called for repealing law that made sex without disclosing HIV status a felony

    September 25, 2026
  • Figma stock jumps 6% as BofA backs AI outlook

    July 7, 2026
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock